Lumithera Valeda
​
The Lumithera Valeda is a non-invasive light therapy used to treat certain types of dry age-related macular degeneration (AMD). The Valeda uses photobiomodulation (PBM), a combination of safe light wavelengths produced by light-emitting diodes, to treat the retina and slow disease progression. PBM is thought to work by reducing oxidative stress and tissue inflammation.
The Valeda is the first FDA-approved treatment for intermediate stage AMD and the only non-invasive FDA-approved treatment for non-central geographic atrophy (advanced dry AMD). The Valeda treatment has been available in Europe for several years and is now available in the United States. Eyes with specific findings and vision between 20/32 and 20/70 may be eligible for treatment. Treatment consists of a cycle of nine short light therapy sessions over three to four weeks. Treatment can be repeated every four months.
A comprehensive retinal examination with imaging is critical to determine eligibility for treatment and to provide a pre-treatment baseline. Treatments are currently provided in our Walnut Creek office. Because it is a new type of treatment, Valeda treatment is not yet covered by health insurance. To learn more, make an appointment to see one of BARA’s retina specialists.